A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy
Status:
Not yet recruiting
Trial end date:
2025-12-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability,
pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to
human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular
dystrophy (FSHD).